RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Clinical trials for RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA explained in plain language.
Never miss a new study
Get alerted when new RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA trials appear
Sign up with your email to follow new studies for RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to heal wounds in rare skin disease
Disease control Recruiting nowThis study tests whether adding IV IgG treatment to standard VYJUVEK therapy can help wounds heal faster and reduce blistering in people with a severe form of epidermolysis bullosa (RDEB). The treatment targets antibodies that may interfere with healing. Eight participants will b…
Matched conditions: RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Phase: PHASE1, PHASE2 • Sponsor: M. Peter Marinkovich • Aim: Disease control
Last updated May 26, 2026 06:02 UTC
-
New eye drop aims to stop painful corneal scratches in rare skin disease
Disease control Recruiting nowThis study tests an eye drop called KB803 in 16 people aged 6 months and older with dystrophic epidermolysis bullosa (DEB), a rare genetic condition causing fragile skin and recurrent corneal abrasions. The trial compares KB803 to a placebo to see if it safely reduces the number …
Matched conditions: RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Phase: PHASE3 • Sponsor: Krystal Biotech, Inc. • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
Lab-Grown skin patch could mend wounds for rare blistering disease patients
Disease control Recruiting nowThis early-stage trial tests a new skin graft made from a patient's own cells, genetically modified to produce a missing protein that helps skin stay attached. The graft is designed to be permanent and aims to heal wounds in people with recessive dystrophic epidermolysis bullosa …
Matched conditions: RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Phase: PHASE1, PHASE2 • Sponsor: CHU de Quebec-Universite Laval • Aim: Disease control
Last updated May 19, 2026 11:46 UTC